UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2005-01, Vol.49 (1), p.195-201

2005

Volltextzugriff (PDF)

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Anti-cancer drugs, 2012-03, Vol.23 (3), p.335-341

2012

Volltextzugriff (PDF)

Nitrous Oxide for the Management of Labor Pain: A Systematic Review

Anesthesia and analgesia, 2014-01, Vol.118 (1), p.153-167

2014

Volltextzugriff (PDF)

Abuse-resistant opioid prodrugs that demonstrate oral overdose protection

The journal of pain, 2012-04, Vol.13 (4), p.S73-S73

2012

Volltextzugriff (PDF)

Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor

The Journal of biological chemistry, 1993-02, Vol.268 (5), p.3625-3631

1993

Volltextzugriff (PDF)

Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2006-02, Vol.50 (2), p.788-790

2006

Volltextzugriff (PDF)

Nitrous Oxide for the Management of Labor Pain: A Systematic Review Erratum

Anesthesia and analgesia, 2014-04, Vol.118 (4), p.885

2014

Volltextzugriff (PDF)

In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone

Journal of opioid management, 2017-01, Vol.13 (1), p.39-49

2017

Volltextzugriff (PDF)

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template

Bioorganic & medicinal chemistry letters, 2001-05, Vol.11 (10), p.1293-1296

2001

Volltextzugriff (PDF)

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes

Bioorganic & medicinal chemistry letters, 2001-05, Vol.11 (10), p.1289-1292

2001

Volltextzugriff (PDF)

A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein Inhibitor, Dosed Every Two Weeks as First Line Chemotherapy for Advanced Locally Recurrent or Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.6103-6103

2009

Volltextzugriff (PDF)

Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family

Journal of medicinal chemistry, 2002-08, Vol.45 (17), p.3772-3793

2002

Volltextzugriff (PDF)

A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1077-1077

2009

Volltextzugriff (PDF)

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

Blood, 2009-11, Vol.114 (22), p.1673-1673

2009

Volltextzugriff (PDF)

A phase I-II trial of Ispinesib , a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.2148

2009

Volltextzugriff (PDF)

A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8578-8578

2009

Volltextzugriff (PDF)

A Novel Monoclonal Antibody Dependent on Domain 5 of the Platelet-Derived Growth Factor Beta Receptor Inhibits Ligand Binding and Receptor Activation

Growth factors (Chur, Switzerland), 1993, Vol.8 (4), p.253-265

1993

Volltextzugriff (PDF)

Nitrous Oxide for the Management of Labor Pain: A Systematic Review

Survey of anesthesiology, 2014-10, Vol.58 (5), p.230-231

2014

Volltextzugriff (PDF)

Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists

Journal of medicinal chemistry, 2004-04, Vol.47 (8), p.2037-2061

2004

Volltextzugriff (PDF)

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

Bioorganic & medicinal chemistry letters, 2002-04, Vol.12 (7), p.1103-1107

2002

Volltextzugriff (PDF)

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes

Bioorganic & medicinal chemistry letters, 2001-05, Vol.11 (10), p.1293

2001

Volltextzugriff (PDF)

SCIENCE SAFETY

The Science teacher (National Science Teachers Association), 1995-04, Vol.62 (4), p.50-50

Seroogy, J. Jack

1995

Volltextzugriff (PDF)

Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice

Journal of neurochemistry, 2002-02, Vol.80 (3), p.539-547

2002

Volltextzugriff (PDF)

Stress exacerbates experimental Parkinson’s disease

Molecular psychiatry, 2014-06, Vol.19 (6), p.638-640

2014

Volltextzugriff (PDF)

ChemInform Abstract: Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 1. Design of Potent and Specific 3,9-Diazaspiro[5.5]undecanes

ChemInform, 2001-09, Vol.32 (37), p.no-no

2001

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(149)

Publikationsform

Artikel
(158)
Berichte
(1)

Sprache

Englisch
(159)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(84)
Animals
(68)
Biological And Medical Sciences
(45)
Male
(43)
Rats
(43)
Humans
(41)
Fundamental And Applied Biological Sciences. Psychology
(34)
Female
(31)
Neurosciences
(26)
Neurosciences & Neurology
(26)
Vertebrates: Nervous System And Sense Organs
(25)
Immunology
(22)
Mice
(22)
Central Nervous System
(21)
Allergy And Immunology
(17)
Immunohistochemistry
(17)
Rats, Inbred Strains
(16)
Medical Sciences
(15)
Central Neurotransmission. Neuromudulation. Pathways And Receptors
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Nitrous Oxide for the Management of Labor Pain: A Systematic Review

Abuse-resistant opioid prodrugs that demonstrate oral overdose protection

Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor

Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects

Nitrous Oxide for the Management of Labor Pain: A Systematic Review Erratum

In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes

A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein Inhibitor, Dosed Every Two Weeks as First Line Chemotherapy for Advanced Locally Recurrent or Metastatic Breast Cancer

Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family

A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

A phase I-II trial of Ispinesib , a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with chemotherapy for metastatic disease or recurrence

A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

A Novel Monoclonal Antibody Dependent on Domain 5 of the Platelet-Derived Growth Factor Beta Receptor Inhibits Ligand Binding and Receptor Activation

Nitrous Oxide for the Management of Labor Pain: A Systematic Review

Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes

SCIENCE SAFETY

Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice

Stress exacerbates experimental Parkinson’s disease

ChemInform Abstract: Spirocyclic Nonpeptide Glycoprotein IIb-IIIa Antagonists. Part 1. Design of Potent and Specific 3,9-Diazaspiro[5.5]undecanes

Suchergebnisse filtern